United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025
United Therapeutics (UTHR) has announced it will release its fourth quarter and full year 2024 financial results before market open on Wednesday, February 26, 2025. The detailed quarterly results will be published via press release at approximately 6:30 a.m. Eastern Time.
The company will host a public webcast at 9:00 a.m. Eastern Time on the same day, which will be accessible through United Therapeutics' investor relations website. A replay of the webcast will remain available for one year. United Therapeutics operates as a public benefit (PBC), focusing on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.
United Therapeutics (UTHR) ha annunciato che rilascerà i risultati finanziari del quarto trimestre e dell'intero anno 2024 prima dell'apertura del mercato il mercoledì 26 febbraio 2025. I risultati trimestrali dettagliati saranno pubblicati tramite comunicato stampa intorno alle 6:30 a.m. Eastern Time.
La società ospiterà un webcast pubblico alle 9:00 a.m. Eastern Time
United Therapeutics (UTHR) ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 antes de la apertura del mercado el miércoles 26 de febrero de 2025. Los resultados trimestrales detallados se publicarán a través de un comunicado de prensa aproximadamente a las 6:30 a.m. Eastern Time.
La empresa llevará a cabo un webcast público a las 9:00 a.m. Eastern Time el mismo día, que será accesible a través del sitio web de relaciones con inversores de United Therapeutics. Una repetición del webcast estará disponible durante un año. United Therapeutics opera como una Public Benefit Corporation (PBC), enfocándose en desarrollar nuevas terapias y tecnologías farmacéuticas para ampliar la disponibilidad de órganos transplantables.
United Therapeutics (UTHR)는 2025년 2월 26일 수요일에 시장 개장 전에 2024년 4분기 및 연간 재무 결과를 발표할 것이라고 발표했습니다. 자세한 분기 결과는 동부 표준시 6:30 a.m.에 보도 자료를 통해 발표될 예정입니다.
회사는 같은 날 동부 표준시 9:00 a.m.에 공개 웹캐스트를 개최하며, 이는 United Therapeutics의 투자자 관계 웹사이트를 통해 접근할 수 있습니다. 웹캐스트의 재생은 1년 동안 제공될 것입니다. United Therapeutics는 공익 법인(PBC)으로 운영되며, 이식 가능한 장기 가용성을 확장하기 위해 새로운 제약 치료법과 기술을 개발하는 데 중점을 두고 있습니다.
United Therapeutics (UTHR) a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année entière 2024 avant l'ouverture du marché le mercredi 26 février 2025. Les résultats trimestriels détaillés seront publiés par communiqué de presse vers 6:30 a.m. Eastern Time.
La société organisera un webcast public à 9:00 a.m. Eastern Time le même jour, qui sera accessible via le site web des relations avec les investisseurs de United Therapeutics. Un enregistrement du webcast sera disponible pendant un an. United Therapeutics fonctionne en tant que Public Benefit Corporation (PBC), en se concentrant sur le développement de nouvelles thérapies et technologies pharmaceutiques pour accroître la disponibilité des organes transplantables.
United Therapeutics (UTHR) hat angekündigt, dass es seine Finanzzahlen für das vierte Quartal und das gesamte Jahr 2024 vor der Markteröffnung am Mittwoch, den 26. Februar 2025 veröffentlichen wird. Die detaillierten Quartalszahlen werden voraussichtlich um 6:30 a.m. Eastern Time über eine Pressemitteilung veröffentlicht.
Das Unternehmen wird am selben Tag um 9:00 a.m. Eastern Time ein öffentliches Webcast veranstalten, das über die Investor-Relations-Website von United Therapeutics zugänglich sein wird. Eine Aufzeichnung des Webcasts wird ein Jahr lang verfügbar sein. United Therapeutics operiert als Public Benefit Corporation (PBC) und konzentriert sich darauf, neuartige pharmazeutische Therapien und Technologien zu entwickeln, um die Verfügbarkeit transplantierbarer Organe zu erhöhen.
- None.
- None.
United Therapeutics will host a public webcast Wednesday, February 26, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location.
United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.
You can learn more about what it means to be a PBC here: unither.com/PBC.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of February 19, 2025, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219740073/en/
For Further Information Contact:
Dewey Steadman at (202) 919-4097 (media/investors)
Harry Silvers at (301) 578-1401 (investors)
https://ir.unither.com/contact-ir
Source: United Therapeutics Corporation
FAQ
When will United Therapeutics (UTHR) report Q4 and full year 2024 earnings?
What time is UTHR's Q4 2024 earnings webcast?
How long will UTHR's Q4 2024 earnings webcast replay be available?
What is United Therapeutics' (UTHR) status as a public benefit ?
